玻璃体内地塞米松植入剂（Ozurdex）治疗眼部弓形虫病。

IF 1.8 4区医学 Q3 OPHTHALMOLOGY Journal of Ophthalmology Pub Date : 2024-07-15 eCollection Date: 2024-01-01 DOI:10.1155/2024/6685092

Yongwei Zhou, Fangyuan Zhen, Jiahui Wu, Shasha Wang, Xiaoyan Lu, Ge Yang, Zhirou Hu, Fei Chen, Qiuming Li, Shuqian Dong

{"title":"玻璃体内地塞米松植入剂（Ozurdex）治疗眼部弓形虫病。","authors":"Yongwei Zhou, Fangyuan Zhen, Jiahui Wu, Shasha Wang, Xiaoyan Lu, Ge Yang, Zhirou Hu, Fei Chen, Qiuming Li, Shuqian Dong","doi":"10.1155/2024/6685092","DOIUrl":null,"url":null,"abstract":"This study aimed to evaluate the efficacy and safety of intravitreal dexamethasone implants in the treatment of ocular toxocariasis (OT). A retrospective analysis was performed on 6 cases in which laboratory tests diagnosed OT. All patients were administered with intravitreal dexamethasone implants with or without vitrectomy. The average follow-up time was 19.7 months. All operated eyes achieved anatomic success, and all patients' visual acuity was improved. Five of these six had a visual acuity of 20/100, and three had final acuity of 20/40 or even better. Intravitreal dexamethasone implants can be used to treat different types of OT, which not only effectively control inflammation and improve the patient's vision but also reduce the use of systemic glucocorticoids.","PeriodicalId":16674,"journal":{"name":"Journal of Ophthalmology","volume":"2024 ","pages":"6685092"},"PeriodicalIF":1.8000,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11262872/pdf/","citationCount":"0","resultStr":"{\"title\":\"Intravitreal Dexamethasone Implant (Ozurdex) for Ocular Toxocariasis.\",\"authors\":\"Yongwei Zhou, Fangyuan Zhen, Jiahui Wu, Shasha Wang, Xiaoyan Lu, Ge Yang, Zhirou Hu, Fei Chen, Qiuming Li, Shuqian Dong\",\"doi\":\"10.1155/2024/6685092\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This study aimed to evaluate the efficacy and safety of intravitreal dexamethasone implants in the treatment of ocular toxocariasis (OT). A retrospective analysis was performed on 6 cases in which laboratory tests diagnosed OT. All patients were administered with intravitreal dexamethasone implants with or without vitrectomy. The average follow-up time was 19.7 months. All operated eyes achieved anatomic success, and all patients' visual acuity was improved. Five of these six had a visual acuity of 20/100, and three had final acuity of 20/40 or even better. Intravitreal dexamethasone implants can be used to treat different types of OT, which not only effectively control inflammation and improve the patient's vision but also reduce the use of systemic glucocorticoids.\",\"PeriodicalId\":16674,\"journal\":{\"name\":\"Journal of Ophthalmology\",\"volume\":\"2024 \",\"pages\":\"6685092\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2024-07-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11262872/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Ophthalmology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1155/2024/6685092\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2024/6685092","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

本研究旨在评估玻璃体内地塞米松植入剂治疗眼弓形虫病（OT）的有效性和安全性。研究对 6 例经实验室检查确诊为 OT 的病例进行了回顾性分析。所有患者均接受了玻璃体内地塞米松植入治疗，无论是否进行了玻璃体切除术。平均随访时间为 19.7 个月。所有接受手术的眼睛都获得了解剖学上的成功，所有患者的视力都得到了改善。这六位患者中，有五位的视力达到了 20/100，有三位的最终视力达到了 20/40，甚至更好。玻璃体内地塞米松植入物可用于治疗不同类型的 OT，不仅能有效控制炎症，改善患者视力，还能减少全身糖皮质激素的使用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Intravitreal Dexamethasone Implant (Ozurdex) for Ocular Toxocariasis.

This study aimed to evaluate the efficacy and safety of intravitreal dexamethasone implants in the treatment of ocular toxocariasis (OT). A retrospective analysis was performed on 6 cases in which laboratory tests diagnosed OT. All patients were administered with intravitreal dexamethasone implants with or without vitrectomy. The average follow-up time was 19.7 months. All operated eyes achieved anatomic success, and all patients' visual acuity was improved. Five of these six had a visual acuity of 20/100, and three had final acuity of 20/40 or even better. Intravitreal dexamethasone implants can be used to treat different types of OT, which not only effectively control inflammation and improve the patient's vision but also reduce the use of systemic glucocorticoids.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Ophthalmology MEDICINE, RESEARCH & EXPERIMENTAL-OPHTHALMOLOGY

CiteScore

4.30

自引率

5.30%

发文量

194

审稿时长

6-12 weeks

期刊介绍： Journal of Ophthalmology is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies related to the anatomy, physiology and diseases of the eye. Submissions should focus on new diagnostic and surgical techniques, instrument and therapy updates, as well as clinical trials and research findings.